Recursion Pharmaceuticals, Inc. · NASDAQ:RXRX
Recursion Pharmaceuticals — Investor Presentation (January 2022)
34 slides from Recursion Pharmaceuticals's investor presentation, Jan 10, 2022
Slide 1: Recursion – January 10, 2022
Exhibit 99.1 th January 10 , 2022
Slide 2: Forward-looking statements
2 This presentation and any accompanying discussion or documents may contain information that includes or is based upon forward‐ looking statements within the meaning of the Securities Litigation Reform Act of 1995. These forward‐looking statements are based on our current expectations, estimates an
Slide 3: Recursion is a clinical stage Pharmatech company
3 3 Recursion is a clinical stage Pharmatech company Mapping and Navigating biology designed to bring better medicines to patients faster and at lower cost via an Internal Pipeline and Partnerships The Leading Pharmatech Mapping & Navigating Internal Pipeline Partnerships 13 Petabytes of proprietary
Slide 4: Drug development productivity and pricing pressures
4 Political sentiment the world over, The number of new drug approvals is up and increasingly in the U.S., against only 47% over the last 25 years and first in high drug prices will create class drug approvals have fallen 17% over 2 additional pressure the past decade 60% of sales growth of the top
Slide 5: Relationships found by the Recursion OS across five pathways
5 All primary relationships found by the Recursion Well‐known primary relationships found by the OS between key members of five pathways: Recursion OS between key members of five pathways: JAK/STAT | SWI/SNF | TGFβ | RAS | Proteasome JAK/STAT | SWI/SNF | TGFβ | RAS | Proteasome
Slide 6: Technology has reshuffled major industries
Technology has reshuffled major industries by bringing order and prediction to complex systems aes gs] Solas
Slide 7: Profile, aggregate and analyze, algorithmic inference
7 1 Profile real systems 1 2 Aggregate and analyze Capture high‐dimensional Aggregate data to create data to create a digital record Real (atoms) digital maps of reality of reality (things, places, behaviors, preferences, etc) Digital (bits) 3 2 Algorithmic Inference 3 Navigate digital maps to predi
Slide 8: How we build maps of biology
How we build maps of biology
Slide 9: How we build maps of biology
How we build maps of biology 9 Digitization of Complex Biology Automated Execution at Scale Up to Proprietary High‐Dimensional Biological Data Experiments per week Biological and Chemical Diversity ML/AI‐Based Analysis Human cell types Small Molecules Supercomputer on Earth Arrayed Cytokines CRISPR
Slide 10: How we navigate our maps of biology
How we navigate our maps of biology to rapidly identify novel insights that can drive better programs faster
Slide 11: Recursion visualizes its Maps in different ways
Recursion visualizes its Maps in different ways. Below is a Map of thousands of new chemical entities, clustered by chemical similarity and colored by potency, which demonstrated a strong anti‐inflammatory response on the Recursion OS To the left, shared for the first time ever, is whole‐ genome arr
Slide 12: Mitochondrial-related genes cluster together
Many known mitochondrial‐related genes cluster together along with a few less well‐known genes 12
Slide 13: JAK/STAT genes cluster together
JAK1 Many known JAK/STAT genes cluster together along with a few less well‐known genes 13
Slide 14: JAK/STAT pathway clustered by strength of interaction
JAK1 JAK1 JAK1 The JAK/STAT pathway now clustered by strength of interaction, including both similar genes (red) and ‘opposite’ genes (blue) – note both expected and less well‐known genes that could serve as novel hypotheses 14
Slide 15: 20S and 26S proteasome clusters
20S Subunit 26S Subunit The 20S and 26S proteosomes are another of hundreds of expected clusters that give confidence in this Map, one of many we have built – however the most exciting elements of each map are the tens of thousands of unknown and unexplored high‐confidence relationships 15
Slide 16: Traditional approach vs Recursion approach
16 Traditional Approach Recursion Approach MAP OF BIOLOGY LIMITATIONS BENEFITS World’s literature reviewed >200B predicted relationships from 1. Millions of disparate journal 1. Massive, relatable >100M highly reproducible experiments articles and publications proprietary map of searchable biology 2
Slide 17: Preliminary program efficiency data vs industry
17 Preliminary data shown is the average of all our programs since late 2017. All industry data adapted from Paul, et al. Nature Reviews Drug Discovery. (2010) 9, 203–214
Slide 18: Mapping and Navigating Biology has demonstrated leading indicators of efficiency
Mapping and Navigating Biology has demonstrated leading indicators * of efficiency including scale een) CLINICAL, try ° eee © Genta ae) PRECLINICAL (© mmene ctcxsonr resistance © ramon Laid esse Poy ces iiomre soe ° Bre oe) = ine A son © parece Grates a DIscovERY (Sroowconasee (© eancenmaumorveniny
Slide 19: Pipeline strategy
19 Pipeline strategy • Advance programs where we Oncology have a data arbitrage • Focus on capital efficient Asset Sales / therapeutic areas Internal Pipeline Commercialization, Inflammation & Licenses / ‐ licensing and asset Immunology Commercialization Internal Pipeline Rare Genetic sales Diseases
Slide 20: Cerebral cavernous malformation program
20 PREVALENCE CAUSE LOF mutations in genes CCM1, CCM2 & CCM3, key for maintaining the structural integrity of the vasculature due to US + EU5 unknown mechanisms PATHOPHYSIOLOGY OUR REASON TO BELIEVE Vascular malformations of the CNS leading Efficacy in Recursion OS as well as functional to focal neu
Slide 21: NF2 meningioma program
21 INCIDENCE CAUSE LOF mutations in NF2 tumor suppressor gene US + EU5 PATHOPHYSIOLOGY OUR REASON TO BELIEVE Efficacy in Recursion OS, cellular, & animal Inherited rare CNS tumor syndrome leading models; suppression of aberrant ERK, AKT, and to loss of hearing and mobility, other focal S6 pathway ac
Slide 22: Familial adenomatous polyposis program
22 PREVALENCE CAUSE Inactivating mutations in the tumor suppressor gene APC US + EU5 PATHOPHYSIOLOGY OUR REASON TO BELIEVE Efficacy in the Recursion OS shows that Polyps throughout the GI tract with specific MEK 1/2 inhibitors had a specific extremely high risk of malignant effect in context of APC
Slide 23: GM2 gangliosidosis program
23 PREVALENCE CAUSE LOF mutations in lysosomal beta‐hexosaminidase subunit genes leading to neuronal GM2 US + EU5 accumulation PATHOPHYSIOLOGY OUR REASON TO BELIEVE Efficacy on the Recursion OS of a unique GM2 + lipofuscin accumulation leads PKCß/GSK3ß dual inhibitor stimulating cellular to complete
Slide 24: C. difficile infection program
24 INCIDENCE CAUSE Release of C. Difficile toxins by colonizing bacterium causes degradation of colon cell junction, toxin transit to bloodstream, and morbidity to host US + EU5 PATHOPHYSIOLOGY OUR REASON TO BELIEVE Highly recurrent infectious disease Efficacy on the Recursion OS identified a new wi
Slide 25: Tumor-intrinsic immune resistance
Tumor‐intrinsic immune resistance STK11 Target Alpha Target Beta More... REC‐ Gene B 648918 BIRC2 Gene A • Goal: Identify novel compounds capable of re‐sensitizing tumors with tumor‐ intrinsic resistance factors to checkpoint therapy Gene A Similar • Phenomap insight: Novel compound (REC‐648918) ide
Slide 26: Tumor-targeted precision therapeutics
Tumor‐targeted precision therapeutics Hepatocellular Carcinoma MYC CDK12 More... REC‐65029 • Goal: Identify novel compounds capable of sensitizing HRD‐negative ovarian and 2.5μM other tumors to PARP inhibition Similar 1.0μM • Phenomap insight: Inhibition of target Gene A (for example, with REC‐65029
Slide 27: Team credentials
Team Credentials Gender: % Women 45% 400+ Employees today Below VP VP and above 41% Advanced degrees 45% Life Sciences ‐ biology, chemistry, development, etc. Tech ‐ Data science, software engineering, automation, etc. Strategic Operations 27
Slide 28: Recursion OS: today, near-term, intermediate-term
28 Today Intermediate‐Term Near‐Term Recursion OS Continued digital chemistry and Clinical Predictions Enables quality, reliability, repeatability predictive ADMET OS build and scale
Slide 29: Near-term and medium-term milestones
29 Near‐Term Milestones Medium‐term milestones • Rec‐994 for CCM Ph2a clinical start in Q1• Multiple POC readout(s) for AI‐discovered programs • Rec‐2882 for NF2 Ph2/3 clinical start in Q1• Potential additional partnership in large, intractable area of biology • Rec‐4881 for FAP Ph2 clinical start i
Slide 30: Impact
IMPACT
Slide 31: Board of Directors and Executive Team
Board of Directors DEAN LI, MD/PHD CHRIS GIBSON, PHD BLAKE BORGESON, PHD ZAVAIN DAR Recursion Co‐founder, Co‐founder & CEO Recursion Co‐founder, Board Partner, Lux Capital President of Merck Research member Machine Intelligence Labs Research Institute ZACHARY BOGUE, JD ROBERT HERSHBERG, TERRY‐ANN BU
Slide 32: Forward program growth
Forward program growth Significant program growth • Growing economic opportunity • Reduction of binary risks (1) ‘Unique Perturbations’ refers to the number of gene, soluble factor, cell and/or compound combinations physically explored. (2) Includes approximately 500,000 compounds from Bayer’s propr
Slide 33: Pipeline size versus peer companies
Company Early Discovery – Preclinical Clinical / Commercial Assets 1318 1018 113 712 7 (multiple through collaboration) 12 >504 Pipeline data from company websites as of 11/08/2021. Trademarks are the property of their respective owners and used for informational and educational purposes only.
Slide 34: Trademarks and analysis notes
Trademarks are the property of their respective owners and used for informational purposes only. Analysis as of April 2021.
Recursion Pharmaceuticals — Investor Presentation (January 2022) on 6ix